Anthony Wang's Research at UCLA: Advancing Neurosurgery and Brain Tumor Treatment

Anthony Wang, MD, a distinguished neurosurgeon at UCLA, is making significant contributions to the fields of neurosurgery and brain tumor treatment. His work spans from innovative approaches to treating brain aneurysms to pioneering clinical trials for aggressive pediatric brain cancers. This article delves into Dr. Wang's research, highlighting his work on intracranial aneurysms (IAs), groundbreaking cancer vaccine trials, and his dedication to improving patient outcomes.

Background of Anthony Wang

Dr. Anthony Wang is a neurosurgeon based in Los Angeles, CA, specializing in brain and spinal tumors, cerebrovascular neurosurgery, pediatric neurosurgery, and skull base surgery. He completed his medical education at Duke University School of Medicine and residency training at the University of Michigan. Dr. Wang further specialized with fellowships in cerebrovascular & skull base surgery at the University of Miami and pediatric neurosurgery at the University of Washington. As an Associate Professor at Ronald Reagan UCLA Medical Center, Dr. Wang is recognized for his expertise in neurosurgical oncology, cerebrovascular neurosurgery, and moyamoya disease. He has published extensively on topics such as glioma therapy and microsurgery for intracranial aneurysms. Additionally, he leads clinical trials focused on treatments for glioma and intracerebral hemorrhage.

Intracranial Aneurysm Research

Hemodynamic Factors in Aneurysm Growth

While image-derived predictors of intracranial aneurysm (IA) rupture have been well-explored, current understanding of IA growth is limited. Pulsatility index (PI) and wall shear stress pulsatility index (WSSPI) are important metrics measuring temporal hemodynamic instability. However, they have not been investigated in IA growth research. Dr. Wang's research has focused on the hemodynamic factors contributing to the growth of intracranial aneurysms (IAs). One study utilized 3D images to construct vascular models of 16 stable and 20 growing cases, verified using Geodesic techniques. With an overall mean follow-up period of 25 months, cases exhibiting a 10% or higher increase in diameter were considered growing. Patient-specific, pulsatile simulations were performed, and hemodynamic calculations were computed at 5 important regions of each aneurysm (inflow artery, aneurysm neck, body, dome, and outflow artery). Index values were compared between growing and stable IAs using ANCOVA controlling for aneurysm diameter.

The study revealed that growing IAs exhibited significantly higher intrasaccular PI, intrasaccular WSSPI, intrasaccular spatial flow rate deviation, and intrasaccular spatial wall shear stress (WSS) deviation compared to stable IAs. These results indicate that a high degree of hemodynamic variations within IAs is linked to growth, even after controlling for morphological parameters. Further, evaluation of PI in conjunction with WSSPI yielded a highly accurate predictive model of IA growth.

Significance of Hemodynamic Variations

Scatterplots of pulsatile flow rates and wall shear stress (WSS) over a cardiac cycle among stable and growing cases. Bars represent average values within the group of cases at that particular time point. Results from flow simulations were calculated at 6 specific time points, which correspond to the 6 time points presented in this figure. Line graphs illustrating significant interactions between image modality and growth status for wall shear stress pulsatility index (WSSPI) at aneurysm body (A) and size ratio (B). ANCOVA revealed significant interactions between image modality and growth status when WSSPI at aneurysm body and size ratio were treated as dependent variables (F=4.19; P=0.049; and F=6.36; P=0.017, respectively). Furthermore, there was a significant main effect of growth status on WSSPIbody (F=11.21; P=0.002) and significant main effects of both image modality and growth status on size ratio (F=6.31; P=0.018; and F=15.33; P<0.001, respectively). Receiver operating characteristic (ROC) curve performance measure of stepwise logistic regression predictive model.

These findings highlight the importance of hemodynamic factors in predicting IA growth, suggesting that monitoring PI and WSSPI could improve risk assessment and treatment planning.

Pediatric Aneurysms

Treating aneurysms in children is particularly complex due to their rarity and the unique anatomical challenges they present. Each case requires a multidisciplinary approach, involving specialists from various medical fields to determine the best course of treatment. Unlike adults, children are more likely to present symptoms due to aneurysm growth rather than rupture, which can make early diagnosis more feasible. However, the rarity and complexity of pediatric aneurysms make research and collaboration crucial to improving outcomes.

Clinical Trial for Diffuse Hemispheric Glioma

Developing a Personalized Cancer Vaccine

In an effort to combat one of the most lethal forms of pediatric brain cancer, researchers at the UCLA Health Jonsson Comprehensive Cancer Center, including Dr. Anthony Wang, are launching a clinical trial to evaluate the safety and effectiveness of a cancer vaccine targeting H3 G34-mutant diffuse hemispheric glioma. This aggressive brain tumor is typically found in adolescents and young adults.

Understanding H3 G34-Mutant Diffuse Hemispheric Glioma (DHG)

This type of brain tumor is primarily characterized by a particular mutation of the H3-3A gene, which encodes an important regulatory component on histone H3. This mutation leads to significant disruptions in RNA processing, with wide-ranging influences on cancer behavior and response to treatment. The vaccine, developed at UCLA, is designed to target these genetic mutations in these tumors.

UCLA's Pioneering Role in Immunotherapy

UCLA Health is one of just a few centers in the United States developing advanced immunotherapies for brain cancer and the only center investigating immunotherapy for this particular type of glioma. Dr. Anthony Wang, director of the Pediatric Brain Tumor Program at UCLA Health and the principal investigator of the trial, explains that these cancers exhibit escape pathways, allowing small populations of cells to survive initial treatment and adapt. The data from pre-clinical studies makes researchers hopeful that an active, targeted cancer vaccine will adapt with the tumor to eliminate cancer cells more effectively.

How the Vaccine Works

The vaccine works by arming a patient’s dendritic cells, the most efficient activator of the body’s immune system, to target products of the altered RNA regulation that defines this cancer type. Once activated against these targets, the patient’s dendritic cells are then injected back into the patient. Dendritic cell vaccination has already shown promise in treating some other forms of cancer, including glioblastoma, adding years of life for a subset of patients with a disease that often only has a lifespan of months.

Trial Enrollment and Manufacturing

This UCLA trial will begin with patients over 18 years old and will then expand to include patients as young as 5 years old, who have a confirmed diagnosis of H3 G34-mutant diffuse hemispheric glioma. The UCLA Human Gene and Cell Facility will manufacture this new dendritic cell vaccine. The facility’s team of experts, led by Dr. Dawn Ward and Dr. Sujna Raval-Fernandes, provides the skill and resources needed to manufacture the vaccine for a much larger number of patients that meet FDA good manufacturing practice standards.

Research Collaboration

The laboratory research leading to this trial has been in development by Wang for several years, in collaboration with Dr. Linda Liau, chair of neurosurgery at UCLA Health, and Dr. Robert Prins, professor in the departments of neurosurgery and molecular and medical pharmacology at the David Geffen School of Medicine at UCLA.

Targeting Tumor Antigens

Prins explains that effective cancer immunotherapies require a deep understanding of the tumor antigens targeted by the immune system. The histone H3 G34R mutation significantly alters mRNA regulation, inducing a conserved set of mRNA splicing changes that result in neoantigens potentially targetable by T lymphocytes. The UCLA team, in conjunction with professor Yi Xing from the Children’s Hospital of Philadelphia, developed a computational tool named IRIS (Isoform peptides from RNA splicing for Immunotherapy target Screening) that predicts products of altered RNA regulation likely to trigger an immune response. Using this tool, the team has identified several neoantigen targets stemming from dysregulated RNA processing, which have proven to be effective targets in laboratory experiments.

Potential Implications

Liau emphasizes that this clinical trial represents a novel and potentially transformative approach to treating high-grade gliomas in children and young adults. Immunotherapy has brought a sea change in the treatment of hematologic cancers, even in the initial stages of development, and clearly has a critical role to play in solid tumors, as well.

Read also: Davis's College Career

Wang is particularly excited by the new targeting strategy, but notes that this is only the beginning of the innovations the group will be bringing to trial in the near future. He also emphasizes that cancers affecting children often are fundamentally different than cancers affecting older adults, and the differences between the pediatric and classical forms of glioblastoma encapsulate this distinction very well.

The Bee Foundation and Brain Aneurysm Prevention

Dr. Wang also collaborates with organizations like The Bee Foundation for Brain Aneurysm Prevention. In a discussion with Cat Navarro Lee, a brain aneurysm survivor, and Erin Kreszl, co-founder of The Bee Foundation, Dr. Wang discussed advancements in aneurysm treatment, pediatric care, and the importance of community support.

Minimally Invasive Techniques

Dr. Wang’s career aligned with the revolutionary advancements in aneurysm treatment, particularly the development of minimally invasive techniques like aneurysm coils. These innovations transformed the field, reducing the need for traditional open-skull procedures and improving patient outcomes.

Genetic Factors in Brain Aneurysm Risk

According to Dr. Wang, while certain genetic susceptibilities exist, aneurysms are more commonly linked to lifestyle and vascular health factors rather than directly inherited traits. Current research, including work by Dr. Wang and Dr. Achyut Chen at UCLA, is exploring the genetic and epigenetic influences on aneurysm formation, with the goal of improving risk assessment and prevention strategies. For individuals with two or more first-degree relatives who have experienced aneurysms, screening may be recommended.

Post-Treatment Support

Dr. Wang emphasized the critical need for post-treatment support, including access to neurorehabilitation, cognitive therapy, and family education. Funding will directly contribute to patient care at UCLA, helping aneurysm survivors recover, providing resources for affected families, and supporting individuals impacted by both brain aneurysms and the recent devastating California wildfires.

Hope for the Future

Over the past 15 years, brain aneurysm research has evolved significantly. The introduction of cutting-edge technology, a better understanding of genetic risk factors, and advancements in minimally invasive procedures have all contributed to better outcomes for patients. Dr. Wang remains optimistic about the future, particularly in the areas of early detection and risk stratification, which will allow doctors to intervene before an aneurysm becomes life-threatening.

A Personal Story of Recovery

Dr. Wang's dedication extends beyond research and clinical trials. He played a critical role in the successful treatment of a UCLA student, Pai, who suffered a severe brain hemorrhage caused by a ruptured aneurysm. Pai's story is a testament to the importance of timely intervention and the expertise of medical professionals like Dr. Wang.

Pai's Experience

Pai doesn’t remember any of what she went through; she has no recollection of the seizures, the ambulance ride, the surgeries or the coma. Rehab, which involved physical, occupational and speech therapy, was grueling. Physically, she bounced back quickly. Mentally, things were hazy for a while. Pai couldn’t remember anything for more than a few seconds. “For months, I didn’t actually have any concept of, ‘This is what had happened to me.’ I was just regurgitating (the facts),” she says. “It was like a random series of events that, at the time, I could not connect to actually being me at all. I think especially because I was so mobile, talkative, and - as far as I could tell - not looking or feeling like somebody that just had a brain aneurysm … I was like, ‘Why is everyone freaking out? It was through speech therapy that Pai began slowly rebuilding her ability to remember - something she’d need to continue progressing toward her college degree. Wang reassured her that her memories and intellect were still intact.

The Importance of Words

Pai believes “the universe brought her UCLA” because it was where she needed to be when she faced a potentially fatal health crisis. “Truly anything is possible,” Pai said. “There is no limit to the power of words.

tags: #anthony #wang #ucla #research